Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Translational research and Cancer Plan].

G Vassal1, L Borella, A Pierre

  • 1Cancéropôle Ile-de-France, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10, France. gilles.vassal@igr.fr

Bulletin Du Cancer
|December 25, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between type 2 diabetes and depressive symptoms after a 1-year follow-up in an older adult Mediterranean population.

Journal of endocrinological investigation·2024
Same author

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Halo effect of a Mediterranean-lifestyle weight-loss intervention on untreated family members' weight and physical activity: a prospective study.

International journal of obesity (2005)·2021
Same author

First Direct Measurement of ^{22}Mg(α,p)^{25}Al and Implications for X-Ray Burst Model-Observation Comparisons.

Physical review letters·2020
Same author

Polypharmacy is a risk factor for hospital admission due to a fall: evidence from the English Longitudinal Study of Ageing.

BMC public health·2020
Same author

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib.

BMC pharmacology & toxicology·2020
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
Same journal

[Robotics in oncological surgery].

Bulletin du cancer·2026
See all related articles
This summary is machine-generated.

The French Cancer Plan 2003-2007 prioritizes translational research to bridge the gap between discoveries and patient care. This strategy aims to enhance cancer research by fostering collaboration and patient-centric knowledge exchange.

Area of Science:

  • Oncology
  • Translational Research
  • Medical Research

Context:

  • The French Cancer Plan 2003-2007 emphasized translational research to improve patient outcomes.
  • Translational research in cancerology is an emerging and often misunderstood field.
  • A multidisciplinary working group was formed to define translational research and its challenges.

Purpose:

  • To define translational research in cancerology.
  • To outline the challenges and opportunities within this research domain.
  • To establish a strategy for implementing translational research in France.

Summary:

  • Translational research requires close patient involvement for bidirectional knowledge transfer.
  • It facilitates the application of scientific discoveries to clinical practice.

Related Experiment Videos

  • It also enables patient observations to inform fundamental research.

    • Impact:

    • To make translational research in France attractive, competitive, and efficient.
    • To foster robust public-private partnerships in cancer research.
    • To accelerate the translation of research findings into patient benefits.